No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
15 or 45 mg |
- |
- |
- |
- |
[1] 67 |
2 |
30 or 60 mg |
- |
- |
- |
- |
[1] 67 |
3 |
30 or 90 mg |
- |
- |
- |
- |
[1] 67 |
4 |
Amias |
- |
- |
- |
- |
[1] 67 |
5 |
Amlodipine |
Amlodipine |
D00615, D02914, D07450 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[4] 51, 65, 67, 298 |
6 |
Antihypertensive drugs |
- |
- |
- |
- |
[1] 67 |
7 |
Aprinox |
- |
- |
- |
- |
[1] 67 |
8 |
Arginine |
L-arginine |
D02982 |
- |
- |
[5] 67, 78, 113, 251, 299 |
9 |
Bardoxolone |
Bardoxolone |
D09584 |
- |
- |
[7] 66, 67, 84, 85, 86, 218, 222 |
10 |
Bardoxolone methyl |
Bardoxolone methyl |
D09585 |
- |
- |
[7] 66, 67, 84, 85, 86, 218, 222 |
11 |
Bardoxolone methyl capsules |
Bardoxolone methyl |
D09585 |
- |
- |
[4] 66, 67, 86, 222 |
12 |
Bardoxolone methyl oral capsule |
Bardoxolone methyl |
D09585 |
- |
- |
[1] 67 |
13 |
Bendroflumethiazide |
Bendroflumethiazide |
D00650 |
- |
- |
[1] 67 |
14 |
Bisoprolol |
Bisoprolol |
D00634, D02342 |
[1] ADRB1 |
[10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 67, 86, 113 |
15 |
Bosutinib |
Bosutinib |
D03252 |
[2] ABL1, SRC |
[45] Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
[2] 2, 67 |
16 |
C03xa01 |
- |
- |
- |
- |
[2] 67, 72 |
17 |
Calcineurin inhibitors maintenance |
- |
- |
- |
- |
[1] 67 |
18 |
Candesartan |
Candesartan |
D00522 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[2] 58, 67 |
19 |
Cardura |
Doxazosin |
D00608, D07874 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 67 |
20 |
Certican tabletten |
Everolimus |
D02714 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[1] 67 |
21 |
Cilnidipine |
Cilnidipine |
D01173 |
[5] CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[37] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Morphine addiction, Nicotine addiction, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 67 |
22 |
Curcumin |
Curcumin |
- |
- |
- |
[10] 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
23 |
Doxazosin |
Doxazosin |
D00608, D07874 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[2] 57, 67 |
24 |
Emodin |
Emodin |
- |
- |
- |
[1] 67 |
25 |
Everolimus |
Everolimus |
D02714 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[8] 34, 67, 89, 96, 137, 157, 158, 277 |
26 |
Genz-682452 |
Venglustat |
D11633 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[2] 19, 67 |
27 |
Genz-682452-au |
Venglustat |
D11633 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[2] 19, 67 |
28 |
Gz402671 |
- |
- |
- |
- |
[2] 19, 67 |
29 |
High water intake |
Water |
D00001 |
- |
- |
[1] 67 |
30 |
Hydralazine |
Hydralazine |
D01302, D08044 |
[1] AOC3 |
[5] Glycine, serine and threonine metabolism, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, beta-Alanine metabolism |
[1] 67 |
31 |
Hydrochlorothiazide |
Hydrochlorothiazide |
D00340 |
- |
- |
[3] 13, 67, 225 |
32 |
Imidapril |
Imidapril |
D08068 |
[1] ACE |
[4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
[1] 67 |
33 |
Intravenous injection autologous mesenchymal stem cells |
- |
- |
- |
- |
[1] 67 |
34 |
Istin |
- |
- |
- |
- |
[1] 67 |
35 |
Jinarc |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
36 |
Jinarc - tolvaptan tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
37 |
Jinarc 15 mg tablets, jinarc 45 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
38 |
Jinarc 30 mg tablets, 90 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
39 |
Jinarc 30 mg tablets, jinarc 60 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
40 |
JinarcĀ® 15mg tablet |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
41 |
JinarcĀ® 30 tablet |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
42 |
Kd019 (tesevatinib) |
Tesevatinib |
- |
- |
- |
[1] 67 |
43 |
L-arginine |
L-arginine |
D02982 |
- |
- |
[4] 67, 78, 113, 299 |
44 |
Lanreotide |
Lanreotide |
D04666 |
- |
- |
[4] 67, 73, 85, 298 |
45 |
Lisinopril |
Lisinopril |
D00362, D08131 |
[1] ACE |
[4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
[5] 46, 66, 67, 113, 222 |
46 |
Lixivaptan |
Lixivaptan |
D04752 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
47 |
Long-acting somatostatin |
Somatostatin |
D07431 |
[5] SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 67 |
48 |
Losartan |
Losartan |
D00357, D08146 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[18] 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
49 |
Metformin |
Metformin |
D00944, D04966 |
[2] PRKAA1, PRKAA2 |
[19] AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
[16] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
50 |
Monocor |
- |
- |
- |
- |
[1] 67 |
51 |
Ng-monomethyl-l-arginine |
Tilarginine |
- |
- |
- |
[1] 67 |
52 |
Ng-monomethyl-l-arginine (drug) |
Tilarginine |
- |
- |
- |
[1] 67 |
53 |
Niacinamide |
Nicotinamide |
D00036 |
- |
- |
[4] 5, 6, 13, 67 |
54 |
Octeotride |
- |
- |
- |
- |
[1] 67 |
55 |
Octreotide |
Octreotide |
D00442, D06495 |
[1] SSTR2 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[7] 67, 75, 84, 85, 89, 193, 227 |
56 |
Octreotide lar |
Octreotide |
D00442, D06495 |
[1] SSTR2 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[2] 67, 227 |
57 |
Octreotide-lar |
Octreotide |
D00442, D06495 |
[1] SSTR2 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 67 |
58 |
Opc-41061 |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
59 |
Opc-41061 (tolvaptan) |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
60 |
Pasireotide |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[3] 67, 74, 75 |
61 |
Pasireotide lar |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[2] 67, 75 |
62 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
63 |
Placebo |
- |
- |
- |
- |
[20] 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
64 |
Potassium |
Potassium |
D08403 |
- |
- |
[9] 46, 66, 67, 98, 115, 167, 179, 215, 235 |
65 |
Pravastatin |
Pravastatin |
D00893, D08410 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[9] 13, 46, 49, 67, 79, 96, 164, 265, 333 |
66 |
Rad001 |
Everolimus |
D02714 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[5] 34, 67, 89, 96, 158 |
67 |
Ramipril |
Ramipril |
D00421 |
[1] ACE |
[4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
[7] 46, 49, 66, 67, 113, 218, 257 |
68 |
Rapamune |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[5] 2, 60, 66, 67, 158 |
69 |
Rapamune 1mg tablets |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[1] 67 |
70 |
Rapamune*100cpr riv 1mg |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[1] 67 |
71 |
Rapamune*30cpr riv 1mg |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[1] 67 |
72 |
Rapamune*30cpr riv 2mg |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[1] 67 |
73 |
Rapamycin |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[16] 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 158, 256, 278, 279 |
74 |
Saline |
Sodium chloride |
D02056 |
- |
- |
[10] 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
75 |
Samsca |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[2] 67, 72 |
76 |
Samsca 15 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
77 |
Samsca 30 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
78 |
Sandostatin lar |
- |
- |
- |
- |
[4] 67, 84, 193, 227 |
79 |
Sandostatina lar |
- |
- |
- |
- |
[1] 67 |
80 |
Sar402671, gz402671 or gz/sar402671 |
- |
- |
- |
- |
[2] 19, 67 |
81 |
Sirolimus |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[30] 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
82 |
Somatostatin |
Somatostatin |
D07431 |
[5] SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[2] 67, 78 |
83 |
Somatuline autosolution |
- |
- |
- |
- |
[1] 67 |
84 |
Spironolactone |
Spironolactone |
D00443 |
[1] NR3C2 |
[1] Aldosterone-regulated sodium reabsorption |
[6] 58, 67, 86, 113, 218, 225 |
85 |
Sugar pill |
- |
- |
- |
- |
[7] 6, 49, 67, 70, 86, 206, 226 |
86 |
Telmisartan |
Telmisartan |
D00627 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[2] 66, 67 |
87 |
Tesevatinib |
Tesevatinib |
- |
- |
- |
[1] 67 |
88 |
Tetracosactin |
- |
- |
- |
- |
[1] 67 |
89 |
Tolvaptan |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[3] 67, 72, 225 |
90 |
Tolvaptan (opc-41061) |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
91 |
Tolvaptan 15 mg tablet |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
92 |
Tolvaptan 15 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
93 |
Tolvaptan 15mg |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
94 |
Tolvaptan 30 mg tablet |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
95 |
Tolvaptan 30 mg tablets |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
96 |
Tolvaptan 30mg |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
97 |
Tolvaptan 7.5 mg tablet |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
98 |
Tolvaptan ir |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
99 |
Tolvaptan mr |
Tolvaptan |
D01213 |
[1] AVPR2 |
[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[1] 67 |
100 |
Tripterygium |
Tripterygium wilfordii whole |
- |
- |
- |
[8] 46, 66, 67, 96, 162, 222, 224, 271 |
101 |
Tripterygium wilfordii |
Tripterygium wilfordii whole |
- |
- |
- |
[6] 46, 66, 67, 222, 224, 271 |
102 |
Triptolide |
Triptolide |
- |
- |
- |
[1] 67 |
103 |
Triptolide-containing formulation |
Triptolide |
- |
- |
- |
[1] 67 |
104 |
Unknown |
- |
- |
- |
- |
[1] 67 |
105 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[8] 6, 67, 84, 93, 94, 95, 96, 97 |
106 |
Venglustat |
Venglustat |
D11633 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[1] 67 |
107 |
Venglustat gz/sar402671 |
Venglustat |
D11633 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[1] 67 |
108 |
Venglustat gz402671 |
Venglustat |
D11633 |
[1] UGCG |
[2] Metabolic pathways, Sphingolipid metabolism |
[1] 67 |
109 |
Water |
Water |
D00001 |
- |
- |
[18] 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
110 |
Zestril |
Lisinopril |
D00362, D08131 |
[1] ACE |
[4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
[2] 67, 222 |